Work

Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma

Year: 2026

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2026.2719622

Authors: Yu-Fan Huang, Jia-Jing Qin, Xiao-Qin Wu, Hui Liu, Susu Luo, Zhe-Qi Xu

Institution: University of Shanghai for Science and Technology

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province

Awards: G6068193753, G7938519575

OpenAlex ID: W7203644343

FWCI:

Cites: 29

Cited by:

Related to: